

Immunex Corporation

Docket No.: 2968-B

DECLARATION

As a below-named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe that I am an original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TWEAK RECEPTOR

the specification of which

☒ is attached hereto.

OR

☐ was filed on as United States Application No. or PCT International Application No.

I hereby state that I have reviewed and understand the contents of said specification, including the claims. I acknowledge the duty to disclose information that is known to me and material to patentability of the subject claimed invention in accordance with 37 C.F.R. §1.56.

☐ I hereby claim the benefit under 35 U.S.C. §120 of the United States application(s) and PCT international application(s) designating the United States that are listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) or PCT international application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application.

Application No.

Filed

☒ I hereby claim the benefit under 35 U.S.C. §119(e) of the United States provisional patent application(s) listed below:

Application No.

Filed

60/172,878

12/20/99

60/203,347

05/10/00

Table 1. Demographic and clinical characteristics of the study population	
Age (years)	65.2 ± 12.5
Gender (male/female)	102/108
Education (years)	12.5 ± 2.1
Marital status (married/divorced/widowed)	150/30/20
Occupation (retired/working)	150/30
Smoking status (smoker/non-smoker)	80/120
Alcohol consumption (yes/no)	40/160
Comorbidities (hypertension/diabetes/cholesterol)	120/50/80
Medication (antidepressants/antipsychotics)	100/20
Duration of illness (years)	15.2 ± 8.5
Severity of illness (mild/moderate/severe)	100/50/50
Family history of mental illness (yes/no)	30/170
Social support (high/low)	100/100
Stressors (work/family/health)	150/100/50
Quality of life (high/low)	100/100
Healthcare utilization (frequent/infrequent)	50/150
Insurance status (private/public)	100/100
Geographical location (urban/rural)	120/80
Season of admission (spring/summer/autumn/winter)	40/40/40/40
Referral source (hospital/clinic/private)	100/50/50
Consent status (yes/no)	150/0
Dropouts (yes/no)	10/140
Lost to follow-up (yes/no)	5/145
Completed study (yes/no)	135/15
Final outcome (recovery/no recovery)	100/35
Follow-up duration (months)	24.5 ± 6.2
Adverse events (yes/no)	10/140
Adherence to treatment (high/low)	100/35
Side effects (yes/no)	20/130
Healthcare costs (high/low)	50/100
Patient satisfaction (high/low)	100/35
Healthcare provider satisfaction (high/low)	100/35
Overall study results (positive/negative)	100/35
Conclusions (effective/ineffective)	100/35
Recommendations (yes/no)	100/35
Future research (yes/no)	100/35
Publication status (published/unpublished)	100/35
Impact on practice (yes/no)	100/35
Policy implications (yes/no)	100/35
Public awareness (high/low)	100/35
Healthcare system (yes/no)	100/35
Government support (yes/no)	100/35
Community involvement (yes/no)	100/35
Research funding (yes/no)	100/35
Collaboration (yes/no)	100/35
Transparency (yes/no)	100/35
Accountability (yes/no)	100/35
Integrity (yes/no)	100/35
Confidentiality (yes/no)	100/35
Security (yes/no)	100/35
Privacy (yes/no)	100/35
Consent (yes/no)	100/35
Information (yes/no)	100/35
Education (yes/no)	100/35
Training (yes/no)	100/35
Supervision (yes/no)	100/35
Evaluation (yes/no)	100/35
Improvement (yes/no)	100/35
Success (yes/no)	100/35
Completion (yes/no)	100/35
Finalization (yes/no)	100/35
Conclusion (yes/no)	100/35
Summary (yes/no)	100/35
Abstract (yes/no)	100/35
Introduction (yes/no)	100/35
Methods (yes/no)	100/35
Results (yes/no)	100/35
Discussion (yes/no)	100/35
Conclusion (yes/no)	100/35
References (yes/no)	100/35
Appendix (yes/no)	100/35
Index (yes/no)	100/35
Table of contents (yes/no)	100/35
Executive summary (yes/no)	100/35
Key words (yes/no)	100/35
Keywords (yes/no)	100/35
Subject terms (yes/no)	100/35
MeSH terms (yes/no)	100/35
Indexing (yes/no)	100/35
Classification (yes/no)	100/35
Terminology (yes/no)	100/35
Language (yes/no)	100/35
Style (yes/no)	100/35
Format (yes/no)	100/35
Version (yes/no)	100/35
Update (yes/no)	100/35
Revision (yes/no)	100/35
Correction (yes/no)	100/35
Withdrawal (yes/no)	100/35
Retraction (yes/no)	100/35
Amendment (yes/no)	100/35
Supplement (yes/no)	100/35
Erratum (yes/no)	100/35
Notice (yes/no)	100/35
Alert (yes/no)	100/35
Subscription (yes/no)	100/35
Access (yes/no)	100/35
Usage (yes/no)	100/35
Impact (yes/no)	100/35
Reach (yes/no)	100/35
Engagement (yes/no)	100/35
Interaction (yes/no)	100/35
Collaboration (yes/no)	100/35
Partnership (yes/no)	100/35
Network (yes/no)	100/35
Community (yes/no)	100/35
Society (yes/no)	100/35
World (yes/no)	100/35
Universe (yes/no)	100/35
Population (yes/no)	100/35
Group (yes/no)	100/35
Category (yes/no)	100/35
Class (yes/no)	100/35
Type (yes/no)	100/35
Form (yes/no)	100/35
Shape (yes/no)	100/35
Size (yes/no)	100/35
Color (yes/no)	100/35
Texture (yes/no)	100/35
Sound (yes/no)	100/35
Sight (yes/no)	100/35
Smell (yes/no)	100/35
Taste (yes/no)	100/35
Touch (yes/no)	100/35
Feeling (yes/no)	100/35
Thought (yes/no)	100/35
Emotion (yes/no)	100/35
Behavior (yes/no)	100/35
Action (yes/no)	100/35
Event (yes/no)	100/35
Occurrence (yes/no)	100/35
Incident (yes/no)	100/35
Case (yes/no)	100/35

Table 1. Demographic and clinical characteristics of the study population	
Age (years)	65.2 ± 12.5
Gender (male/female)	102/108
Education (years)	12.5 ± 2.1
Marital status (married/divorced/widowed)	150/30/20
Occupation (retired/working)	150/30
Smoking status (smoker/non-smoker)	80/120
Alcohol consumption (yes/no)	40/160
Comorbidities (hypertension/diabetes/cholesterol)	120/50/80
Medication (antidepressants/antipsychotics)	100/20
Duration of illness (years)	15.2 ± 8.5
Severity of illness (mild/moderate/severe)	100/50/50
Family history of mental illness (yes/no)	30/170
Social support (high/low)	100/100
Stressors (work/family/health)	150/100/50
Quality of life (high/low)	100/100
Healthcare utilization (frequent/infrequent)	50/150
Insurance status (private/public)	100/100
Geographical location (urban/rural)	120/80
Season of admission (spring/summer/autumn/winter)	40/40/40/40
Referral source (hospital/clinic/private)	100/50/50
Consent status (yes/no)	150/0
Dropouts (yes/no)	10/140
Lost to follow-up (yes/no)	5/145
Completed study (yes/no)	135/15
Final outcome (recovery/no recovery)	100/35
Follow-up duration (months)	24.5 ± 6.2
Adverse events (yes/no)	10/140
Adherence to treatment (high/low)	100/35
Side effects (yes/no)	20/130
Healthcare costs (high/low)	50/100
Patient satisfaction (high/low)	100/35
Healthcare provider satisfaction (high/low)	100/35
Overall study results (positive/negative)	100/35
Conclusions (effective/ineffective)	100/35
Recommendations (yes/no)	100/35
Future research (yes/no)	100/35
Publication status (published/unpublished)	100/35
Impact on practice (yes/no)	100/35
Policy implications (yes/no)	100/35
Public awareness (high/low)	100/35
Healthcare system (yes/no)	100/35
Government support (yes/no)	100/35
Community involvement (yes/no)	100/35
Research funding (yes/no)	100/35
Collaboration (yes/no)	100/35
Transparency (yes/no)	100/35
Accountability (yes/no)	100/35
Integrity (yes/no)	100/35
Confidentiality (yes/no)	100/35
Security (yes/no)	100/35
Privacy (yes/no)	100/35
Consent (yes/no)	100/35
Information (yes/no)	100/35
Education (yes/no)	100/35
Training (yes/no)	100/35
Supervision (yes/no)	100/35
Evaluation (yes/no)	100/35
Improvement (yes/no)	100/35
Success (yes/no)	100/35
Completion (yes/no)	100/35
Finalization (yes/no)	100/35
Conclusion (yes/no)	100/35
Summary (yes/no)	100/35
Abstract (yes/no)	100/35
Introduction (yes/no)	100/35
Methods (yes/no)	100/35
Results (yes/no)	100/35
Discussion (yes/no)	100/35
Conclusion (yes/no)	100/35
References (yes/no)	100/35
Appendix (yes/no)	100/35
Index (yes/no)	100/35
Table of contents (yes/no)	100/35
Executive summary (yes/no)	100/35
Key words (yes/no)	100/35
Keywords (yes/no)	100/35
Subject terms (yes/no)	100/35
MeSH terms (yes/no)	100/35
Indexing (yes/no)	100/35
Classification (yes/no)	100/35
Terminology (yes/no)	100/35
Language (yes/no)	100/35
Style (yes/no)	100/35
Format (yes/no)	100/35
Version (yes/no)	100/35
Update (yes/no)	100/35
Revision (yes/no)	100/35
Correction (yes/no)	100/35
Withdrawal (yes/no)	100/35
Retraction (yes/no)	100/35
Amendment (yes/no)	100/35
Supplement (yes/no)	100/35
Erratum (yes/no)	100/35
Notice (yes/no)	100/35
Alert (yes/no)	100/35
Subscription (yes/no)	100/35
Access (yes/no)	100/35
Usage (yes/no)	100/35
Impact (yes/no)	100/35
Reach (yes/no)	100/35
Engagement (yes/no)	100/35
Interaction (yes/no)	100/35
Collaboration (yes/no)	100/35
Partnership (yes/no)	100/35
Network (yes/no)	100/35
Community (yes/no)	100/35
Society (yes/no)	100/35
World (yes/no)	100/35
Universe (yes/no)	100/35
Population (yes/no)	100/35
Group (yes/no)	100/35
Category (yes/no)	100/35
Class (yes/no)	100/35
Type (yes/no)	100/35
Form (yes/no)	100/35
Shape (yes/no)	100/35
Size (yes/no)	100/35
Weight (yes/no)	100/35
Height (yes/no)	100/35
Length (yes/no)	100/35
Width (yes/no)	100/35
Depth (yes/no)	100/35
Volume (yes/no)	100/35
Area (yes/no)	100/35
Perimeter (yes/no)	100/35
Surface (yes/no)	100/35
Interior (yes/no)	100/35
Exterior (yes/no)	100/35
Inside (yes/no)	100/35
Outside (yes/no)	100/35
Within (yes/no)	100/35
Without (yes/no)	100/35
Among (yes/no)	100/35

Table 1. Demographic and clinical characteristics of the study population	
Age (years)	65.2 ± 12.5
Gender (male/female)	102/108
Education (years)	12.5 ± 2.1
Marital status (married/divorced/widowed)	150/30/20
Occupation (retired/working)	150/30
Smoking status (smoker/non-smoker)	80/120
Alcohol consumption (yes/no)	40/160
Comorbidities (hypertension/diabetes/cholesterol)	120/50/80
Medication (antidepressants/antipsychotics)	100/20
Duration of illness (years)	15.2 ± 8.5
Severity of illness (mild/moderate/severe)	100/50/50
Family history of mental illness (yes/no)	30/170
Social support (adequate/inadequate)	120/80
Stressors (work/family/health)	150/30/20
Quality of life (high/low)	100/100
Overall health (good/fair/poor)	120/50/30
Life satisfaction (satisfied/dissatisfied)	100/100
Future outlook (positive/negative)	120/80
Religious beliefs (strong/weak)	100/100
Community involvement (active/passive)	120/80
Financial stability (stable/unstable)	100/100
Physical health (good/fair/poor)	120/50/30
Mental health (stable/unstable)	100/100
Social functioning (good/fair/poor)	120/50/30
Occupational functioning (good/fair/poor)	100/100
Family functioning (good/fair/poor)	120/50/30
Healthcare utilization (high/low)	100/100
Health insurance (yes/no)	150/30
Healthcare access (easy/difficult)	120/80
Healthcare costs (affordable/unaffordable)	100/100
Healthcare quality (good/fair/poor)	120/50/30
Healthcare satisfaction (satisfied/dissatisfied)	100/100
Healthcare trust (high/low)	120/80
Healthcare engagement (active/passive)	100/100
Healthcare compliance (high/low)	120/80
Healthcare adherence (high/low)	100/100
Healthcare utilization (high/low)	120/80
Healthcare access (easy/difficult)	100/100
Healthcare costs (affordable/unaffordable)	120/80
Healthcare quality (good/fair/poor)	100/100
Healthcare satisfaction (satisfied/dissatisfied)	120/80
Healthcare trust (high/low)	100/100
Healthcare engagement (active/passive)	120/80
Healthcare compliance (high/low)	100/100
Healthcare adherence (high/low)	120/80
Healthcare utilization (high/low)	100/100
Healthcare access (easy/difficult)	120/80
Healthcare costs (affordable/unaffordable)	100/100
Healthcare quality (good/fair/poor)	120/80
Healthcare satisfaction (satisfied/dissatisfied)	100/100
Healthcare trust (high/low)	120/80
Healthcare engagement (active/passive)	100/100
Healthcare compliance (high/low)	120/80
Healthcare adherence (high/low)	100/100
Healthcare utilization (high/low)	120/80
Healthcare access (easy/difficult)	100/100
Healthcare costs (affordable/unaffordable)	120/80
Healthcare quality (good/fair/poor)	100/100
Healthcare satisfaction (satisfied/dissatisfied)	120/80
Healthcare trust (high/low)	100/100
Healthcare engagement (active/passive)	120/80
Healthcare compliance (high/low)	100/100
Healthcare adherence (high/low)	120/80
Healthcare utilization (high/low)	100/100
Healthcare access (easy/difficult)	120/80
Healthcare costs (affordable/unaffordable)	100/100
Healthcare quality (good/fair/poor)	120/80
Healthcare satisfaction (satisfied/dissatisfied)	100/100
Healthcare trust (high/low)	120/80
Healthcare engagement (active/passive)	100/100
Healthcare compliance (high/low)	120/80
Healthcare adherence (high/low)	100/100
Healthcare utilization (high/low)	120/80
Healthcare access (easy/difficult)	100/100
Healthcare costs (affordable/unaffordable)	120/80
Healthcare quality (good/fair/poor)	100/100
Healthcare satisfaction (satisfied/dissatisfied)	120/80
Healthcare trust (high/low)	100/100
Healthcare engagement (active/passive)	120/80
Healthcare compliance (high/low)	100/100
Healthcare adherence (high/low)	120/80
Healthcare utilization (high/low)	100/100
Healthcare access (easy/difficult)	120/80
Healthcare costs (affordable/unaffordable)	100/100
Healthcare quality (good/fair/poor)	120/80
Healthcare satisfaction (satisfied/dissatisfied)	100/100
Healthcare trust (high/low)	120/80
Healthcare engagement (active/passive)	100/100
Healthcare compliance (high/low)	120/80
Healthcare adherence (high/low)	100/100
Healthcare utilization (high/low)	120/80
Healthcare access (easy/difficult)	100/100
Healthcare costs (affordable/unaffordable)	120/80
Healthcare quality (good/fair/poor)	100/100
Healthcare satisfaction (satisfied/dissatisfied)	120/80
Healthcare trust (high/low)	100/100
Healthcare engagement (active/passive)	120/80
Healthcare compliance (high/low)	100/100
Healthcare adherence (high/low)	120/80
Healthcare utilization (high/low)	100/100
Healthcare access (easy/difficult)	120/80
Healthcare costs (affordable/unaffordable)	100/100
Healthcare quality (good/fair/poor)	120/80
Healthcare satisfaction (satisfied/dissatisfied)	100/100
Healthcare trust (high/low)	120/80
Healthcare engagement (active/passive)	100/100
Healthcare compliance (high/low)	120/80
Healthcare adherence (high/low)	100/100
Healthcare utilization (high/low)	120/80
Healthcare access (easy/difficult)	100/100
Healthcare costs (affordable/unaffordable)	120/80
Healthcare quality (good/fair/poor)	100/100
Healthcare satisfaction (satisfied/dissatisfied)	120/80
Healthcare trust (high/low)	100/100
Healthcare engagement (active/passive)	120/80
Healthcare compliance (high/low)	100/100
Healthcare adherence (high/low)	120/80
Healthcare utilization (high/low)	100/100
Healthcare access (easy/difficult)	120/80
Healthcare costs (affordable/unaffordable)	100/100
Healthcare quality (good/fair/poor)	120/80

[illegible]

Table 1. Demographic and clinical characteristics of the study population	
Age (years)	65.2 ± 12.5
Gender (male/female)	102/108
Education (years)	12.5 ± 2.1
Marital status (married/divorced/widowed)	150/30/20
Occupation (retired/working)	150/30
Smoking status (smoker/non-smoker)	80/120
Alcohol consumption (yes/no)	40/160
Comorbidities (hypertension/diabetes/cholesterol)	120/50/80
Medication (antidepressants/antipsychotics)	100/20
Duration of illness (years)	15.2 ± 8.5
Severity of illness (mild/moderate/severe)	100/50/50
Family history of mental illness (yes/no)	30/170
Social support (high/low)	100/100
Stressors (work/family/health)	150/100/50
Quality of life (high/low)	100/100
Healthcare utilization (frequent/infrequent)	50/150
Insurance status (private/public)	100/100
Geographical location (urban/rural)	120/80
Season of admission (spring/summer/autumn/winter)	40/40/40/40
Referral source (hospital/clinic/private)	100/50/50
Consent status (yes/no)	150/0
Dropouts (yes/no)	10/140
Lost to follow-up (yes/no)	5/145
Completed study (yes/no)	135/15
Final outcome (recovery/no recovery)	100/35
Follow-up duration (months)	24.5 ± 6.2
Adverse events (yes/no)	10/140
Adherence to treatment (high/low)	100/35
Side effects (yes/no)	20/130
Healthcare costs (high/low)	50/100
Patient satisfaction (high/low)	100/35
Healthcare provider satisfaction (high/low)	100/35
Overall study results (positive/negative)	100/35
Conclusions (effective/ineffective)	100/35
Recommendations (yes/no)	100/35
Future research (yes/no)	100/35
Publication status (published/unpublished)	100/35
Impact on practice (yes/no)	100/35
Policy implications (yes/no)	100/35
Public awareness (high/low)	100/35
Healthcare system (yes/no)	100/35
Government support (yes/no)	100/35
Community involvement (yes/no)	100/35
Research funding (yes/no)	100/35
Collaboration (yes/no)	100/35
Transparency (yes/no)	100/35
Accountability (yes/no)	100/35
Integrity (yes/no)	100/35
Confidentiality (yes/no)	100/35
Security (yes/no)	100/35
Privacy (yes/no)	100/35
Consent (yes/no)	100/35
Information (yes/no)	100/35
Education (yes/no)	100/35
Training (yes/no)	100/35
Supervision (yes/no)	100/35
Evaluation (yes/no)	100/35
Improvement (yes/no)	100/35
Success (yes/no)	100/35
Completion (yes/no)	100/35
Finalization (yes/no)	100/35
Conclusion (yes/no)	100/35
Summary (yes/no)	100/35
Abstract (yes/no)	100/35
Introduction (yes/no)	100/35
Methods (yes/no)	100/35
Results (yes/no)	100/35
Discussion (yes/no)	100/35
Conclusion (yes/no)	100/35
References (yes/no)	100/35
Appendix (yes/no)	100/35
Index (yes/no)	100/35
Table of contents (yes/no)	100/35
Executive summary (yes/no)	100/35
Key words (yes/no)	100/35
Keywords (yes/no)	100/35
Subject terms (yes/no)	100/35
MeSH terms (yes/no)	100/35
Indexing (yes/no)	100/35
Classification (yes/no)	100/35
Terminology (yes/no)	100/35
Language (yes/no)	100/35
Style (yes/no)	100/35
Format (yes/no)	100/35
Version (yes/no)	100/35
Update (yes/no)	100/35
Revision (yes/no)	100/35
Correction (yes/no)	100/35
Withdrawal (yes/no)	100/35
Retraction (yes/no)	100/35
Amendment (yes/no)	100/35
Supplement (yes/no)	100/35
Erratum (yes/no)	100/35
Notice (yes/no)	100/35
Alert (yes/no)	100/35
Subscription (yes/no)	100/35
Access (yes/no)	100/35
Usage (yes/no)	100/35
Impact (yes/no)	100/35
Reach (yes/no)	100/35
Engagement (yes/no)	100/35
Interaction (yes/no)	100/35
Collaboration (yes/no)	100/35
Partnership (yes/no)	100/35
Network (yes/no)	100/35
Community (yes/no)	100/35
Society (yes/no)	100/35
World (yes/no)	100/35
Universe (yes/no)	100/35
Population (yes/no)	100/35
Group (yes/no)	100/35
Category (yes/no)	100/35
Class (yes/no)	100/35
Type (yes/no)	100/35
Form (yes/no)	100/35
Shape (yes/no)	100/35
Size (yes/no)	100/35
Weight (yes/no)	100/35
Height (yes/no)	100/35
Length (yes/no)	100/35
Width (yes/no)	100/35
Depth (yes/no)	100/35
Volume (yes/no)	100/35
Area (yes/no)	100/35
Perimeter (yes/no)	100/35
Surface (yes/no)	100/35
Interior (yes/no)	100/35
Exterior (yes/no)	100/35
Inside (yes/no)	100/35
Outside (yes/no)	100/35
Within (yes/no)	100/35
Without (yes/no)	100/35
Among (yes/no)	100/35

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
Steven R. Wiley

Docket No.: 2968-B

Serial No: Not assigned

Group Art Unit: Not assigned

Filed: herewith

Examiner: Not assigned

For: TWEAK RECEPTOR

STATEMENT UNDER 37 C.F.R. 3.73(b) AND
POWER OF ATTORNEY BY ASSIGNEE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

IMMUNEX CORPORATION (hereinafter "IMMUNEX"), a corporation of the State of Washington having a place of business at 51 University Street, Seattle, Washington 98101, is the assignee of the entire right, title, and interest in the above-identified U.S. patent application. Documentary evidence of a chain of title from the original owner(s) to Immunex is demonstrated by:

- ☒ the enclosed copy of an Assignment, the original of which is being filed for recordation by the United States Patent and Trademark Office.

OR

- ☐ the assignment recorded in the United States Patent and Trademark Office at Reel , Frame .

The undersigned, whose title is supplied below, is empowered to sign this statement on behalf of IMMUNEX.

IMMUNEX hereby appoints the registered practitioners at the following Customer Number to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:



22932

Statement Under 37 C.F.R. 3.73(b) and Power of Attorney by Assignee

Docket No. 2968-B

Please send all correspondence and direct telephone calls to the above-identified Customer Number.

Respectfully submitted,

Date December 19, 2000

By Michael K. Kirschner
Michael K. Kirschner
Vice President, Intellectual Property

Enclosure: Copy of Assignment

[illegible]

ASSIGNMENT

WHEREAS, I, Steven R. Wiley, residing at Seattle, Washington, have made an invention entitled "TWEAK RECEPTOR," for which U.S. provisional Patent Application No. 60/172,878 was filed December 20, 1999, U.S. provisional Patent Application No. 60/203,347 was filed May 10, 2000, and for which a U.S. Patent Application was executed on December 19, 2000.

AND, WHEREAS, IMMUNEX CORPORATION, a corporation of the State of Washington, having a principal place of business at 51 University Street, Seattle, Washington 98101 (hereinafter referred to as ASSIGNEE) is desirous of acquiring the entire right and title to and interest in the invention disclosed in said application;

NOW, THEREFORE, for sufficient, good and valuable consideration, the receipt of which is hereby acknowledged, I do hereby sell, assign, and transfer unto said ASSIGNEE my entire right and title to and interest in said applications and said invention(s) and all U.S. and foreign applications and patents on said invention(s) to be held and enjoyed by ASSIGNEE as entirely as the same would have been held and enjoyed by me had this sale, assignment, and transfer not been made, and I do hereby further agree and promise to execute all instruments and render all such assistance as ASSIGNEE may request in order to make and prosecute any and all applications on said invention(s), to enforce any and all patents on said invention(s), and to confirm in ASSIGNEE legal title to said invention(s) and all applications and patents on said invention(s), all without charge to ASSIGNEE but at no expense to me.

Executed at Seattle, Washington, this 19 day of December, 2000.

Steven R. Wiley
Steven R. Wiley

STATE OF WASHINGTON)


) ss.

COUNTY OF KING)

On this 19th day of December, 2000, personally appeared before me Steven R. Wiley, to me known to be the individual named above who executed the within and foregoing instrument, and acknowledged that he signed the same as his free and voluntary act and deed, for the uses and purposes therein mentioned.

Nanci M. Kertson
Nanci M. Kertson

Notary Public in and for the
State of Washington, residing at Seattle, Washington
My appointment expires 4-19-03



005727-454460